Huahai Pharmaceuticals Glong ammonium bromine injection approved by FDA

Pharmaceutical Network November 7th, November 5th, Huahai Pharmaceuticals announced that the company recently received the U.SFDA on the Glong ammonium injection of new drug application (ANDA) has been approved notice, which means that the company is qualified to produce and sell the product in the U.Smarket, the product has not yet been sold in ChinaTable 1: Drug Basic sin
(Source: Listed Company Announcement)the meta-inflammatory of Gromon is mainly applicable to symptoms such as stomach and duodenal ulcers, chronic gastritis, excessive gastric acid secretion, etc., the product was developed by West-Ward Pharmaceuticals and approved for listing in the United States in 1982Currently in the United States, the main manufacturers of the Glong ammonium bromine injection include American RegentUp to now, Huahai Pharmaceuticals has invested about 11.3 million yuan in research and development on the Glong ammonium bromine injection projectFigure 1: 2013-2017 China's public medical institutions terminal antacid and peptic ulcer and bloating drug sales (unit: million yuan)(source: minet China public medical institutions terminal competition pattern)According to the meter net data, in recent years, China's public medical institutions terminal antacidandic acid and peptic ulcer and flatulfied drug market expanded year by year, the first time in 2017 to break 400 billion yuan, the same yearFrom the competitive pattern, TOP10 products mainly include injection of pentoprazole, injection omeprazole, injection of lansolaquine, rebeira intestinal solution, etc, these products are suitable for stomach ulcers, duodenum ulcers, etc, similar to the metamothes of granola ammonium injectionGlong ammonium bromine injection is the first injection approved by Huahai Pharmaceuticals in the U.Smarket, and its approval further enriches the company's existing varieties and dosage forms, is conducive to expanding the market sales of products, enhance the market competitiveness of the company's products, and has a positive impact on the company's operating performanceat present, the domestic market has not been approved for sale of the Gron bromine ammonium injection, Huahai Pharmaceuticals is expected to become the first domestic gross bromine ammonium injection through the "foreign transmission to domestic" way sources: Internet database, announcement of listed companies